Doximity (DOCS) Receives a Hold From Truist Financial
Needham: Reiterates that Do( DOCS.US) holds the rating.
Doximity's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Doximity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Zimmer Biomet Holdings (ZBH), Doximity (DOCS) and Arvinas Holding Company (ARVN)
Doximity (DOCS) Hold Rating Maintained Amid Balanced Growth Prospects and Market Uncertainty
Hold Rating on Doximity Amid Slower Growth and Economic Uncertainty
Barclays Sticks to Its Hold Rating for Doximity (DOCS)
Truist Securities Adjusts Price Target on Doximity to $31 From $29 After 'Strong' Fiscal Q4 Results, Keeps Hold Rating
Analysts Offer Insights on Healthcare Companies: Koninklijke Philips (PHG), Doximity (DOCS) and R1 RCM (RCM)
Doximity's Strong Market Position Amidst Economic Headwinds: A Balanced Hold Recommendation
Komo: Upgraded the DOCS.US (DOCS.US) rating from reduced holdings to a neutral rating, with a target price of $25.00.
Doximity Analyst Ratings
JPMorgan Upgrades Doximity to Neutral Rating From Underweight, Price Target Is $25
Doximity Analyst Ratings
Morgan Stanley Maintains Underweight on Doximity, Maintains $25 Price Target
Doximity Analyst Ratings
Doximity Analyst Ratings
JP Morgan Maintains Underweight on Doximity, Raises Price Target to $25
Leerink Partners Initiates Coverage On Doximity With Market Perform Rating, Announces Price Target of $32